Jason Hoitt Biography and Net Worth

Chief Patient Officer of Stoke Therapeutics

Jason Hoitt is the chief patient officer at Stoke Therapeutics, where he is responsible for overseeing the company’s global commercial, medical affairs and manufacturing functions.

Jason has more than 20 years of experience successfully planning and executing launch strategies at leading biopharma companies, with a focus on companies making the transition from clinical to commercial stage. Prior to joining Stoke, Jason served as the chief commercial officer at Provention Bio, where he led pre-launch and launch strategy and execution for Tzield® (teplizumab-mzwv), the first medicine approved to address the underlying autoimmune cause of type 1 diabetes. Before that, Jason served as the chief commercial officer at Dova Pharmaceuticals, where he led launch strategy and execution for DOPTELET® (avatrombopag) for chronic immune thrombocytopenia. Prior to Dova, Jason was a member of the commercial leadership team at Insmed Incorporated, serving as a vice president and head of sales. He previously held senior roles in sales, marketing and medical affairs at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.

Jason holds a B.A. from the College of the Holy Cross.

What is Jason Hoitt's net worth?: The estimated net worth of Jason Hoitt is at least $409.06 thousand as of March 17th, 2026. Mr. Hoitt owns 12,207 shares of Stoke Therapeutics stock worth more than $409,057 as of March 23rd. This net worth estimate does not reflect any other investments that Mr. Hoitt may own. Learn More about Jason Hoitt's net worth.
How do I contact Jason Hoitt?: The corporate mailing address for Mr. Hoitt and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Jason Hoitt's contact information.
Has Jason Hoitt been buying or selling shares of Stoke Therapeutics?: In the last ninety days, Jason Hoitt has sold $119,308.35 in shares of Stoke Therapeutics stock. Most recently, Jason Hoitt sold 1,931 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a transaction totalling $60,517.54. Following the completion of the sale, the insider now directly owns 10,276 shares of the company's stock, valued at $322,049.84. Learn More on Jason Hoitt's trading history.
Who are Stoke Therapeutics' active insiders?: Stoke Therapeutics' insider roster includes Jonathan Allan (General Counsel), Jason Hoitt (Chief Patient Officer), Edward Kaye (), Edward Kaye (Director), Adrian Krainer (Director), Arthur Levin (Director), Huw Nash (COO), Barry Ticho (Insider), and Arthur Tzianabos (Insider). Learn More on Stoke Therapeutics' active insiders.
Are insiders buying or selling shares of Stoke Therapeutics?: In the last twelve months, insiders at the sold shares 42 times. They sold a total of 367,800 shares worth more than $9,809,384.63. The most recent insider tranaction occured on March, 19th when insider Barry Ticho sold 1,461 shares worth more than $43,815.39. Insiders at Stoke Therapeutics own 9.5% of the company. Learn More about insider trades at Stoke Therapeutics.
Information on this page was last updated on 3/19/2026.

Jason Hoitt Insider Trading History at Stoke Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/18/2026	Sell	1,931	$31.34	$60,517.54	10,276
3/17/2026	Sell	1,781	$33.01	$58,790.81	12,207

Jason Hoitt Buying and Selling Activity at Stoke Therapeutics

Stoke Therapeutics Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $34.47

$34.91

50 Day Range

MA: $32.61

$28.70

$38.35

2 Week Range

Now: $34.47

$5.35

$40.22

Volume

17,588 shs

Average Volume

764,054 shs

Market Capitalization

$2.04 billion

P/E Ratio

51.25

Dividend Yield

N/A

Beta

1.07